View Older Stories View More Recent Stories

Feb 7, 2023 08:45AM CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Jan 12, 2023 08:45AM CNS Pharmaceuticals (CNSP) Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Jan 12, 2023 08:45AM CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Jan 11, 2023 01:00PM JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Jan 5, 2023 09:05AM CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
Jan 3, 2023 12:01PM CNS Pharmaceuticals (CNSP) Appoints Faith L. Charles, JD as Chair of the Board of Directors
Jan 3, 2023 12:00PM CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
Dec 8, 2022 09:11AM CNS Pharmaceuticals (CNSP) Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Dec 8, 2022 09:08AM CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Dec 5, 2022 08:05AM CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event
Nov 30, 2022 10:00PM CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
Nov 28, 2022 04:53PM CNS Pharmaceuticals (CNSP) Announces 1-for-30 Reverse Stock Split
Nov 28, 2022 04:53PM CNS Pharmaceuticals Announces Reverse Stock Split
Nov 14, 2022 04:05PM CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 2, 2022 08:45AM CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Oct 10, 2022 09:00AM CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run
Oct 7, 2022 08:00AM CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
Sep 28, 2022 09:05AM CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Sep 23, 2022 09:00AM CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)
Sep 7, 2022 08:45AM CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 15, 2022 08:05AM CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 25, 2022 08:05AM CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022
Jun 23, 2022 08:35AM CNS Pharmaceuticals (CNSP) Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Jun 23, 2022 08:35AM CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Jun 8, 2022 08:35AM CNS Pharmaceuticals (CNSP) Presents Ongoing Berubicin Clinical Trial Design
Jun 8, 2022 08:35AM CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
May 24, 2022 07:00AM CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:35AM CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
May 16, 2022 08:05AM CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 28, 2022 08:36AM CNS Pharmaceuticals (CNSP) Approved by Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 28, 2022 08:35AM CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 13, 2022 10:45AM JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
Apr 12, 2022 08:35AM CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event
Apr 6, 2022 08:35AM CNS Pharmaceuticals (CNSP) Approved to Commence Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 6, 2022 08:35AM CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 5, 2022 08:36AM CNS Pharmaceuticals (CNSP) Granted Swiss Approval for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 5, 2022 08:35AM CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Mar 23, 2022 08:35AM CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 9, 2022 09:20AM CNS Pharmaceuticals (CNSP) Reiterates Operational Progress and Addresses Recent Share Price Activity
Mar 9, 2022 09:20AM CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders
Mar 3, 2022 08:36AM CNS Pharmaceuticals (CNSP) Reports 2021 Results, Provides Corporate Update
Mar 3, 2022 08:35AM CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Jan 20, 2022 08:45AM CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
Jan 12, 2022 10:35AM JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Jan 10, 2022 05:00PM CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Jan 7, 2022 08:05AM CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
Jan 6, 2022 07:01AM CNS Pharmaceuticals (CNSP) Announces 12.1M Share Private Placement at $0.95/sh
Jan 6, 2022 07:00AM CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Dec 2, 2021 08:35AM CNS Pharmaceuticals (CNSP) Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme
Dec 2, 2021 08:35AM CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
View More Recent Stories View Older Stories